key: cord-0991807-vh1m1mlm authors: Privé, Bastiaan M.; Janssen, Marcel J. R.; van Oort, Inge M.; Muselaers, Constantijn H. J.; Jonker, Marianne A.; van Gemert, Willemijn A.; de Groot, Michel; Westdorp, Harm; Mehra, Niven; Verzijlbergen, J. Fred; Scheenen, Tom W. J.; Zámecnik, Patrik; Barentsz, Jelle O.; Gotthardt, Martin; Noordzij, Walter; Vogel, Wouter V.; Bergman, Andries M.; van der Poel, Henk G.; Vis, André N.; Oprea-Lager, Daniela E.; Gerritsen, Winald R.; Witjes, J. Alfred; Nagarajah, James title: Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial date: 2021-11-04 journal: Trials DOI: 10.1186/s13063-021-05733-4 sha: 93b3e4f71f0417d410c21d22654468c21349f51e doc_id: 991807 cord_uid: vh1m1mlm BACKGROUND: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if (177)Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and postpone the need for androgen deprivation therapy (ADT). The original study protocol was published in 2020. Here, we report amendments that have been made to the study protocol since the commencement of the trial. CHANGES IN METHODS AND MATERIALS: Two important changes were made to the original protocol: (1) the study will now use (177)Lu-PSMA-617 instead of (177)Lu-PSMA-I&T and (2) responding patients with residual disease on (18)F-PSMA PET after the first two cycles are eligible to receive additional two cycles of 7.4 GBq (177)Lu-PSMA in weeks 12 and 18, summing up to a maximum of 4 cycles if indicated. Therefore, patients receiving (177)Lu-PSMA-617 will also receive an interim (18)F-PSMA PET scan in week 4 after cycle 2. The title of this study was modified to; “Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer” and is now partly supported by Advanced Accelerator Applications, a Novartis Company. CONCLUSIONS: We present an update of the original study protocol prior to the completion of the study. Treatment arm patients that were included and received (177)Lu-PSMA-I&T under the previous protocol will be replaced. TRIAL REGISTRATION: ClinicalTrials.gov NCT04443062. First posted: June 23, 2020. Prostate cancer is the most common non-skin cancer in males [1] . Despite surgery or external beam radiotherapy (EBRT), between 27% and 53% of patients will have a detectable prostate-specific antigen (PSA) and present with disease recurrence [2] . If there are no curative options, patients with a short PSA doubling time (e.g., <6 months) have a worse prognosis and early androgen deprivation therapy (ADT) is the treatment of choice [3] [4] [5] . While ADT delays disease progression of patients, it is associated with significant side effects and frequently impairs the quality of life [6] . Therefore, there is an increasing interest in treatments to postpone ADT while maintaining a good quality of life. Lately, metastases-directed therapy (MDT) (e.g., EBRT) is showing promising efficacy to postpone ADT or cure selected patients with solely low-grade treatment-related side effects. Studies have reported that approximately 30-40% of patients that underwent MDT are still without ADT 5 years post-irradiation [7] [8] [9] [10] . Particularly, patients with a limited number of metastases (≤5 metastases), the so-called oligometastatic prostate cancer, seem to benefit from MDT [7, 9, 11, 12] . Therefore, several pivotal trials are currently investigating MDT in an oligometastatic setting. All these studies rely on imaging modalities such as positron emission tomography (PET) to detect and target these tumor metastases [13] [14] [15] [16] . The currently favored PET tracers in prostate cancer are Gallium-68 ( 68 Ga) or Fluor-18 ( 18 F)-labeled prostate-specific membrane antigen (PSMA) ligands (PSMA-11, DCFPyL, or PSMA-1007). However, PSMA ligands, such as PSMA-617 & PSMA-I&T, can also be labeled with beta emitters like Lutetium-177 ( 177 Lu) for radioligand therapy to deliver high local radiation doses to tumors directly [17] [18] [19] [20] [21] [22] . 177 Lu-labeled PSMA is a promising new therapeutic approach with the pending registry in the 3rd or 4th line castration-resistant prostate cancer [21] . Recently, we showed that 177 Lu-PSMA is also highly effective in the hormone-sensitive setting with low volume disease because of high tumor uptake of PSMA targeted radioligands in small lesions, such as oligometastatic prostate cancer [17, 18, 23] . Moreover, the favorable toxicity profile of 177 Lu-PSMA seen in our pilot study supports this new treatment in this setting. Therefore, we initiated a prospective randomized multicenter phase II study that evaluates the efficacy of 177 Lu-PSMA in oHSPC to postpone disease progression and to avert the need for ADT. This study protocol was published in 2020, but was recently amended. The changes to the protocol are described in the present report [24] . The original protocol was designed using the PSMA ligand PSMA-I&T, which can be labeled with 177 Lu in our local laboratory following GMP conditions. Unfortunately, due to COVID-19-related issues (e.g., personnel shortage, remote working, and increased demand for hospital resources), the production of 177 Lu-PSMA-I&T for our study did not receive a priority designation in our hospitals. Therefore, the study required a third party for the stable production of 177 Lu-PSMA and a logistical party to supply all participating centers. The study will now use 177 Lu-PSMA-617 as Advanced Accelerator Applications stepped in for support. The study also received a new title "Lutetium-177-PSMA in Oligometastatic Hormone Sensitive Prostate Cancer." As some patients may have a residual disease with good PSMA uptake after two cycles of 7.4 GBq 177 Lu-PSMA, with no or only low-grade side effects, the present protocol enables an additional two cycles if this is thought beneficial for patients. Thus, patients in the therapeutic arm (or those in the control arm that met the primary endpoint and now receive 177 Lu-PSMA) are eligible for another two cycles of 7.4GBq of 177 Lu-PSMA given 12 and 18 weeks after cycle one. To evaluate if the residual disease is present after the first two cycles, patients will also undergo an interim 18 F-PSMA PET scan 4 weeks (±1 week) after cycle two. Since recruitment began in July 2020, only three patients were included prior to the amendments reported above. One patient was allocated to the therapeutic arm and received two cycles of 177 Lu-PSMA-I&T. This patient will be replaced by a new patient under the amended protocol. The two control arm patients will not be replaced and will be eligible to receive 177 Lu-PSMA-617 in case they meet the primary endpoint, which is disease progression within 24 weeks post cycle two. After the publication of the original protocol, the study was amended due to COVID-19-related issues to acquire third-party support for the labeling of the radiopharmaceutical. Therefore, the study will now use 177 Lu-PSMA-617 instead of 177 Lu-PSMA-I&T. In addition, patients with residual disease on 18 F-PSMA PET after the first two cycles are eligible to receive an additional two cycles of 7.4 GBq 177 Lu-PSMA in week 12 and week 18 after cycle one, summing up to a maximum of 4 cycles if necessary. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer Androgen deprivation therapy: evidence-based management of side effects Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer: a prospective study Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, openlabel, phase 2 trial Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations